We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Proteome Sciences plc | AQSE:PRM.GB | Aquis Stock Exchange | Ordinary Share | GB0003104196 | Ordinary Shares 1p |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.50 | 2.50 | 5.00 | 3.75 | 3.50 | 3.50 | 0.00 | 16:29:38 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMPRM
RNS Number : 1887C
Proteome Sciences PLC
24 June 2016
PRESS RELEASE
Proteome Sciences plc
("Company" or the "Group")
AGM Statement and Result of AGM
24 June 2016
At the AGM held earlier today it was announced that revenues from the core biomarker services activities remained buoyant in the first half with a strong order book, including repeat business, and a developing pipeline. TMT revenue growth has continued into 2016 and TMT was highly visible at the recent meeting of the American Society for Mass Spectrometry. The growing recognition of tau as a therapeutic target in Alzheimer's disease should increase interest in new treatments which could favourably affect our compounds targeting CK1d in the tau pathway. We are confident that the business remains on track in 2016 to deliver a significant increase in revenues.
At the AGM all resolutions were duly passed.
- Ends -
For further information please contact:
Hot Features
Premium
Proteome Sciences plc
Dr. Jeremy Haigh, Chief Executive
Officer
Dr. Ian Pike, Chief Operating Tel: +44 (0)1932 865065
Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated
Adviser/Broker) Tel : +44 (0)20 7220
Geoff Nash/James Thompson 0500
Public Relations
IKON Associates Email: adrian@ikonassociates.com
Adrian Shaw Tel: +44 (0)1483 271291
Mobile +44(0)7979 900733
Notes for editors:
About Proteome Sciences plc (www.proteomics.com)
With its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways (SysQuant(R), TMTcalibrator(TM)) and in protein biomarker discovery, validation and assay development.
PS Biomarker Services(R) provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001: 2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.
Proteome Sciences' research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer's disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGPGUBWQUPQUMC
(END) Dow Jones Newswires
June 24, 2016 07:30 ET (11:30 GMT)
1 Year Proteome Sciences Chart |
1 Month Proteome Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
